Download NIH Modular Budget Justification Sample (None of the names used

NIH Modular Budget Justification Sample
(None of the names used here is real; please do not infer them to anyone in reality.)
Personnel Scott Smart, Ph.D., Principal Investigator (2.4 calendar months per year) will be involved in the conception,
design, and supervision of all experiments in this project. Dr. Smart has significant experience in protein chemistry
and molecular virological techniques including virus culture, titering, genetic manipulation, recombinant virus
constructions, and evaluation of virus infectivity. He will train all personnel in his laboratory in the techniques of cellular
and molecular virology, including those related to the major assays used (including handling of HHV-8 and derivative
variants). Dr. Smart will oversee the execution and interpretation of all data generated by all members of the research
group. He will perform some of the experiments and will be available to assist in interpretation of all data generated. He
will write and/or edit all manuscripts resulting from this project. Dr. Smart will also present data at conferences intensive
to basic cancer research, but he will also seek to disseminate new findings at conferences of broad interest to
molecular cancer biologists in general. Dr. Smart is a U.S. Department of Defense Employee, so no salary
compensation will be requested to support his efforts on this project.
Just Wright, Graduate Medical Research Assistant (12.0 calendar months per year) is an M.D./Ph.D. student in the
Emerging Infectious Diseases Program of the USUHS Department of Microbiology and Immunology. He will work
alongside the post-doctoral Fellow on several aspects of this project, particularly those involving culture and derivation
of prostate cancer cell lines. Mr. Wright already has a solid working knowledge of many of the cell lines that will be
used for this study and has generated all the preliminary data that are driving this research. Mr. Wright stipend is
provided by the USUHS School of Medicine, so no salary is requested for him from this grant.
TBD, Postdoctoral Fellow (12.0 calendar months per year), will be responsible for cultivation of recombinant HHV-8,
development of cell culture assays involving immunofluorescence (IFA) as well as transcriptional profiling of gene
expression using real-time and quantitative PCR, generating new cell lines expressing a variety of cellular molecules
predicted to play a role in the inflammatory axis in order to study them in isolation. The fellow will be encouraged to
write manuscripts based on novel findings from the proposed work. This individual will be hired as a Henry M. Jackson
Foundation employee and compensation is requested.
Collaborators/Consultants
Able Collab, Ph.D., Collaborator (0.12 calendar months). Dr. Collab is Assistant Director of the Basic Science
Research Program, and Research Assistant Professor of Surgery. He is the Chief of the Section for Gene Regulation
and Bioinformatics. His expertise is in the regulation, expression and functions of prostate cancer-associated genes
such as PMEPA1, ERG and androgen-regulated genes. His current work focuses on determining the relationship
between oncogenic processes and androgen receptor signaling, as well as developing new approaches towards the
treatment of prostate cancer by synergizing state-of-the-art molecular and in silico bioinformatic methodologies. He is
the recipient of the prestigious CaP Foundation Competitive Award, and an award from the Congressionally Directed
Medical Research Program. Specifically, Dr. Collab will assist in setting up a transcriptome profiling platform along
with the Post-doctoral fellow. He will also serve as a liaison with the Historically black colleges and University
(HBCU) consortium as part of an effort to seed a Health Disparities component derived from this proposal, which
involves looking at differential susceptibility to HHV-8 infection as one of the risk factors for inflammatory prostatitis.
FY 2013 Indirect Costs and Fringe Benefit Rates
* The fringe rate used is 31.51% for Tier 1 employees and 3.15% for Tier 2 employees (all employees in this
proposal are Tier 1).
HJF indirect cost (IDC) is calculated based on the value-added cost base overhead rates. The 33.62% of USU on-site
rate is applied on for all allowable direct cost, less sub-award costs; additional 13.69% of Company-wide G&A rate is
applied on the total direct cost less sub-award. For proposals including subawards, additional 1.02% is applied on
total sub-award costs. These fringe benefit and indirect cost rates were approved by U.S. Army Medical Research
Acquisition Activity as provisional rates on 12/26/2012.